Financial Performance - The net loss for the three months ended March 31, 2025, was $5.1 million, with an accumulated deficit of $126.7 million as of the same date[242]. - The company has not generated any revenue from product sales and expects to incur significant and increasing expenses for the foreseeable future[241][244]. - The company has incurred significant operating losses since inception, primarily funded through private sales of common stock and convertible promissory notes[241]. - The net loss for Q1 2025 was $5.1 million, a reduction of 30% compared to a net loss of $7.2 million in Q1 2024[267]. - Research and development expenses for Q1 2025 were $2.4 million, a decrease of 12% from $2.7 million in Q1 2024[269]. - General and administrative expenses for Q1 2025 were $2.6 million, down 34% from $4.0 million in Q1 2024[270]. - Total operating expenses decreased by 25% to $5.1 million in Q1 2025 from $6.8 million in Q1 2024[267]. - Net cash used in operating activities was $7.1 million for the three months ended March 31, 2025, compared to $3.8 million for the same period in 2024, representing an increase of 86%[291][292]. - The company reported a net loss of $5.1 million for the three months ended March 31, 2025, a decrease from a net loss of $7.2 million in the same period of 2024[291][292]. - The total cash and restricted cash increased by $970,000 in the three months ended March 31, 2025, compared to a decrease of $806,000 in the same period of 2024, indicating a turnaround in cash flow[290]. Funding and Financial Position - The company anticipates needing substantial additional funding to support operations and pursue growth strategies, with potential financing through public or private equity offerings and debt financings[246]. - The company raised gross proceeds of $4.3 million from a public offering of 5,000,000 shares at $0.85 per share on January 10, 2025[275]. - The company entered into a Securities Purchase Agreement on March 28, 2025, resulting in gross proceeds of approximately $3.9 million[283]. - The company increased the maximum aggregate offering amount under the At The Market Offering Agreement from $5.1 million to $11.2 million on February 4, 2025[280]. - The company anticipates an increase in general and administrative expenses as it expands to support growth in research and development activities[262]. - The company raised substantial doubt about its ability to continue as a going concern due to insufficient cash on hand to support operations for at least one year[247]. - The company has concluded that it does not have sufficient cash on hand to support current operations for at least one year from the date of the financial statements issued, raising substantial doubt about its ability to continue as a going concern[297]. - The company anticipates that existing cash will not be sufficient to complete the development of product candidates CLD-101, CLD-201, and CLD-400, requiring further funding[298]. - The company plans to finance cash needs through public or private equity offerings, debt financings, or potential collaboration agreements, which may dilute ownership interests[299]. Research and Development - The FDA approved the IND application for CLD-201 (SuperNova™) in April 2025, with plans to commence a Phase 1 clinical trial by the end of 2025[237]. - A Phase 1b/2 clinical trial for CLD-101 (NeuroNova™) targeting newly diagnosed high-grade gliomas is dependent on the resumption of funding from National Cancer Institute grants, which were frozen in March 2025[235]. - The preclinical program CLD-400 (RTNova) is focused on targeting lung cancer and metastatic solid tumors, showing early signs of resistance to human humoral immunity[240]. - The company has engaged in early discovery research involving Adult Allogeneic Adipose-derived (AAA) stem cells for various therapeutic applications[238]. Management and Governance - Eric Poma, Ph.D., was appointed as CEO effective April 22, 2025, following the resignation of Allan Camaisa[251]. Market and Economic Conditions - The company is not currently exposed to significant market risk related to changes in interest rates or foreign currency exchange rates, but future operations may be subject to such fluctuations[306][307]. - Inflation has not had a material effect on the company's business, financial condition, or results of operations during the three months ended March 31, 2025, and 2024[308]. - The company is currently not exposed to significant market risk related to foreign currency exchange rates, but may face fluctuations in the future due to operations in Europe and Australia[307]. Regulatory and Reporting Status - The company qualifies as an "emerging growth company" (EGC) under the JOBS Act, allowing it to delay the adoption of certain accounting standards until they apply to private companies[309]. - The company is classified as a "smaller reporting company," with a market value of stock held by non-affiliates less than $700 million and annual revenue below $100 million in the most recently completed fiscal year[311]. - The company may continue to rely on exemptions from certain disclosure requirements as a smaller reporting company, including presenting only two years of audited financial statements[312]. - The company will avail itself of exemptions from providing an auditor's attestation report on internal control over financial reporting and reduced disclosure about executive compensation[313]. - Recent accounting standards are not expected to have a material impact on the company's financial statements or operations[314].

Revenue Performance - U.S. fee revenues for Q1 2025 decreased 85% to $2.7 million compared to $18.3 million in Q1 2024, primarily due to decreased crew utilization [81]. - Canadian fee revenues for Q1 2025 increased 48% to $12.5 million compared to $8.5 million in Q1 2024, driven by increased crew utilization and the use of single node channels [82]. - Total revenues for Q1 2025 were $16.1 million, down from $31.6 million in Q1 2024, including a $4.0 million decrease in reimbursable revenues [82]. - The company expects revenue to increase in the U.S. in Q2 2025 due to a strong backlog [76]. Operating Costs and Financial Performance - Total operating costs for Q1 2025 were $15.0 million, representing a 63% decrease from the same period in 2024 [88]. - Adjusted EBITDA for Q1 2025 was $2.3 million, compared to $7.6 million in Q1 2024 [94]. - Net cash provided by operating activities was $1.8 million for Q1 2025, compared to $1.9 million for the same period in 2024 [96]. Capital Expenditures and Investments - Capital expenditures for 2025 are budgeted at $6.0 million, with funding primarily from cash flow from operations and cash reserves [99]. - The company plans to invest in new single node channels to improve revenue and margins through enhanced crew efficiency [78]. Dividends and Shareholder Returns - A special cash dividend of $0.32 per share was declared on March 28, 2024, totaling approximately $9.9 million [100]. Debt and Financial Obligations - As of March 31, 2025, the company has outstanding short-term notes payable totaling $1.5 million, an increase from $168,000 as of December 31, 2024 [103]. - The company has finance leases of $2.2 million as of March 31, 2025, down from $2.4 million as of December 31, 2024 [104]. - The interest rates on outstanding notes payable to finance companies range from 6.35% to 9.74% [105]. - The aggregate maturities of finance leases for the period April 2025 to March 2026 amount to $836,000 [105]. - The Loan Agreement with Dominion Bank provided a secured revolving credit facility of up to $5 million, which was terminated on May 2, 2024 [101]. - As of March 31, 2025, the company has no outstanding letters of credit [102]. Risk Management - The company believes its capital resources will be adequate to meet current operational needs and finance 2025 capital expenditures through cash flow from operations [106]. - There has been no material change in the company's market risk profile during the three months ended March 31, 2025 [110]. - The company is exposed to foreign currency exchange rate risk due to operations in Canada [111]. - The company has not entered into any hedge arrangements or derivative financial instruments [111].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41293 ASPIRE BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 33-3467744 (State or other juris ...

Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41293 ASPIRE BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Dela ...

Financial Performance - The company reported a net income of $184,662 for the three months ended March 31, 2025, compared to a net income of $755,500 for the same period in 2024, indicating a decrease of about 76%[13]. - Basic and diluted net income per ordinary share subject to possible redemption was $0.03 for the three months ended March 31, 2025, down from $0.08 in the same period of 2024[13]. - Net income for the three months ended March 31, 2025, was $184,662, compared to $755,500 for the same period in 2024, indicating a significant decrease in profitability[61]. - Basic and diluted net income per share for the three months ended March 31, 2025, was $0.03, down from $0.08 for the same period in 2024[61]. - As of March 31, 2025, the accumulated deficit increased to $(2,367,937) from $(1,476,823) as of December 31, 2024, reflecting a worsening financial position[15]. Assets and Liabilities - As of March 31, 2025, total assets decreased to $43,602,847 from $73,814,933 as of December 31, 2024, representing a decline of approximately 41%[10]. - Total current liabilities increased to $1,685,746 as of March 31, 2025, from $816,994 as of December 31, 2024, marking an increase of approximately 106%[10]. - Cash held in the Trust Account decreased to $43,594,825 as of March 31, 2025, from $73,784,549 as of December 31, 2024, a reduction of about 41%[10]. - The Company has a working capital deficit of $1,677,724 as of March 31, 2025[40]. - The total amount due to a related company as of March 31, 2025, was $472,926, an increase from $289,780 as of December 31, 2024[80]. Initial Public Offering (IPO) - The Initial Public Offering generated gross proceeds of $69,000,000, with offering costs amounting to $2,070,665 and deferred underwriting commissions of $690,000[22]. - The Company completed its Initial Public Offering on December 6, 2023, raising gross proceeds of $69,000,000 from the sale of 6,900,000 Units at $10.00 per Unit[69]. - The IPO generated gross proceeds of $60,000,000 from the sale of 6,000,000 units at an offering price of $10.00 per unit[125]. - An additional $9,000,000 was raised through the full exercise of the Over-Allotment Option by underwriters[125]. - The company incurred $1,380,000 in underwriting discounts and $550,000 in other costs related to the IPO[128]. Business Operations and Future Plans - The company had not commenced any operations as of March 31, 2025, and all activities were related to its formation and Initial Public Offering[21]. - The company anticipates targeting small cap companies in healthcare innovation for future business combinations[20]. - The Company has entered into a definitive Business Combination Agreement with United Hydrogen Group Inc. and its subsidiaries[35]. - Management has raised substantial doubt about the company's ability to continue as a going concern if the initial business combination is not completed within the prescribed time[112]. Cash Flow and Liquidity - Cash flows from operating activities resulted in a net cash used of $224,009 for the three months ended March 31, 2025, compared to $166,970 for the same period in 2024[17]. - The Company’s liquidity is primarily supported by net proceeds from the Initial Public Offering and Private Placement[41]. - As of March 31, 2025, the Company had $7,345 in its bank account[40]. - The Trust Account held $43,594,825 as of March 31, 2025, while the company had a working capital deficit of approximately $1,677,724[110]. Shareholder Information - A total of 2,904,267 shares were redeemed at approximately $10.77 per share, amounting to an aggregate of about $31.27 million[37]. - The Company’s ordinary shares subject to possible redemption totaled 3,995,773 at the redemption amount as of March 31, 2025[55]. - As of March 31, 2025, there were 2,126,000 ordinary shares issued and outstanding, excluding 3,995,773 and 6,900,000 shares subject to possible redemption[85]. - The Sponsor purchased an aggregate of 332,000 Private Units at a price of $10.00 per Private Unit, totaling $3,320,000[72]. Regulatory and Compliance - The company filed a Registration Statement on Form S-1/A on July 24, 2023, which includes specimen unit, ordinary share, and rights certificates[4.1][4.2][4.3]. - Certifications of the Principal Executive Officer and Principal Financial Officer were completed in accordance with the Sarbanes-Oxley Act of 2002[31.1][31.2]. - The Inline XBRL Instance Document and related taxonomy extension documents were filed, indicating compliance with SEC requirements[101.INS][101.SCH][101.CAL][101.DEF][101.LAB][101.PRE].

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41880 AIMEI HEALTH TECHNOLOGY CO., LTD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR (I.R.S. Employer Identification No.) 10 East 53rd Street, Suite 3001 New York, NY 10022 (Address of ...

EX-99.1 2 job_ex991.htm PRESS RELEASE EXHIBIT 99.1 GEE Group Announces Results for the Fiscal 2025 Second Quarter and YTD Jacksonville, FL / May 14, 2025 / Accesswire / GEE Group Inc. (NYSE American: JOB) together with its subsidiaries (collectively referred to as the "Company," "GEE Group," "our" or "we"), a provider of professional staffing services and human resource solutions, today announced consolidated results for the fiscal 2025 second quarter and year to date periods ended March 31, 2025. The Compa ...

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed ...

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) This section summarizes SS Innovations' strong financial performance in Q1 2025 and outlines key business and strategic advancements [First Quarter 2025 Overview](index=1&type=section&id=First%20Quarter%202025%20Overview) SS Innovations reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase year-over-year, driven by higher sales of its SSi Mantra 3 surgical robotic system Q1 2025 Financial Highlights (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $5.1 million | $3.6 million | +40.8% | | Gross Profit | $1.1 million | $0.7 million | +49.3% | | Gross Margin | 21.23% | 20.02% | +121 bps | | Net Loss | $(5.7) million | $(9.8) million | Narrowed | | Net Loss per Share | $(0.03) | $(0.06) | Narrowed | | SSi Mantra Installations | 15 units | 9 units | +66.7% | Q1 2025 Revenue Breakdown and Operational Metrics (vs. Q1 2024) | Category | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | System sales | $4,502,482 | $3,494,759 | +28.8% | | Instrument sales | $477,208 | $118,515 | +302.7% | | Warranty sales | $122,504 | $9,407 | +1,202.3% | | **Total revenue** | **$5,120,610** | **$3,637,693** | **+40.8%** | | SSi Mantra installations | 15 | 9 | +67% | | Cumulative installed base | 78 | 24 | +225% | | SSi Mantra surgeries | 787 | 361 | +118% | | Cumulative surgeries | 3,568 | 981 | +264% | - The company ended the quarter with **$15.9 million** in cash and cash equivalents and zero long-term debt[5](index=5&type=chunk) [Business and Strategic Developments](index=1&type=section&id=Business%20and%20Strategic%20Developments) Following the quarter, the company uplisted its stock to the Nasdaq Capital Market, while focusing on global expansion and key operational milestones - The company is on track to submit a De Novo application for the SSi Mantra 3 system to the U.S. Food and Drug Administration (FDA) by the end of July 2025[1](index=1&type=chunk)[6](index=6&type=chunk) - SS Innovations is pursuing a European Union CE Mark decision, with a target of late 2025[6](index=6&type=chunk) - Subsequent to the quarter end, on April 25, 2025, the company's common stock was uplisted to The Nasdaq Capital Market®[3](index=3&type=chunk) - Key Q1 achievements include: - The SSi Mantra 3 system enabled the world's first robotic cardiac telesurgery - The company debuted a state-of-the-art mobile telesurgery unit in India - Received medical device regulatory approvals in the Philippines and Ukraine[9](index=9&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents the condensed consolidated balance sheets, statements of operations, and cash flows for SS Innovations, highlighting key financial positions and performance metrics [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets grew to $63.5 million from $42.4 million at year-end 2024, largely due to a significant increase in cash and inventory Balance Sheet Summary | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $15,873,217 | $466,500 | | Total Current Assets | $47,619,943 | $27,416,291 | | **Total Assets** | **$63,456,961** | **$42,385,213** | | Total Current Liabilities | $14,996,713 | $21,330,222 | | **Total Liabilities** | **$22,902,671** | **$28,928,110** | | **Total Stockholders' Equity** | **$40,554,290** | **$13,457,103** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, revenues increased 40.8% to $5.1 million, with a significant reduction in stock compensation expense leading to a narrowed net loss of $5.7 million Statement of Operations Summary (Three Months Ended) | Account | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Total Revenue | $5,120,610 | $3,637,693 | | Gross Profit | $1,087,208 | $728,182 | | Total Operating Expenses | $7,009,061 | $10,560,501 | | Loss from Operations | $(5,921,853) | $(9,832,319) | | **Net Loss** | **$(5,681,353)** | **$(9,841,753)** | | Net Loss Per Share (basic and diluted) | $(0.03) | $(0.06) | - Stock compensation expense decreased significantly to **$2.4 million** in Q1 2025 from **$7.1 million** in Q1 2024, which was a primary driver for the reduction in net loss[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company used $6.1 million in cash from operating activities, offset by $22.4 million provided by financing activities, resulting in a net increase in cash of $15.4 million Cash Flow Summary (Three Months Ended) | Activity | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,103,374) | $(2,671,918) | | Net cash used in investing activities | $(872,804) | $(127,255) | | Net cash provided by financing activities | $22,406,019 | $2,638,259 | | **Net change in cash** | **$15,429,841** | **$(160,914)** | | Cash and cash equivalents at end of period | $22,078,788 | $6,895,580 | - Financing activities were primarily driven by **$28 million** in proceeds from the issuance of convertible notes to a principal shareholder[17](index=17&type=chunk) - As a supplemental disclosure, **$30.6 million** of convertible notes, including interest, were converted into common stock during the period[17](index=17&type=chunk) [Company and Product Overview](index=2&type=section&id=Company%20and%20Product%20Overview) This section provides an overview of SS Innovations International, Inc., its mission to democratize robotic surgery, and details its flagship SSi Mantra surgical robotic system [About SS Innovations](index=2&type=section&id=About%20SS%20Innovations) SS Innovations International, Inc. is an American company, headquartered in India, that develops surgical robotic technologies with a mission to make robotic surgery affordable and accessible globally - The company's vision is to democratize robotic surgery by making it affordable and accessible to a larger segment of the global population[8](index=8&type=chunk) - The product portfolio includes the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, which support various procedures including robotic cardiac surgery[8](index=8&type=chunk) [About the SSi Mantra](index=3&type=section&id=About%20the%20SSi%20Mantra) The SSi Mantra is a modular, multi-arm surgical robotic system designed for user-friendliness, featuring advanced technologies and clinical validation across over 100 surgical procedures in India - The system is modular with 3 to 5 robotic arms and features an open-faced ergonomic surgeon command center with a large 3D 4K monitor[10](index=10&type=chunk) - It utilizes over 40 different types of robotic endo-surgical instruments to support specialties including cardiac surgery[10](index=10&type=chunk) - The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures[10](index=10&type=chunk)

united states Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q (Mark One) ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from …… to ……. Commission File Number 0-12114 Cadiz Inc. (Exact name of registrant specified in its charter) Delaware 77-0313235 (State or other jurisdiction of ( ...